-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte Corporation Releases Document on Povorcitinib for Moderate to Severe Hidradenitis Suppurativa Phase 3 Results

Reuters·09/17/2025 12:39:58

Please log in to view news